Rybelsus · DIN 02551039 · 9 mg · tablet
Limited Use, Reason for Use code 740 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 740 required
Write on scriptReason for Use code 740 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 740
Reason for Use code 740
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.
Maximum reimbursed dose: 9mg once daily.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02551039
Manufacturer: Novo Nordisk Canada Inc; listing date 2026-03-31
Health Canada: Marketed since 2026-03-13 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 9 MG · company Novo nordisk canada inc · schedule Schedule d, Prescription
Rybelsus: Formulary list price $7.53 per unit (the source does not state the unit; exact figure $7.5303). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02551039)
Source record
DIN 02551039: Rybelsus
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006012; group id 766; item number 1871; lccId 00430; manufacturer id NOO
Source form: Tab; strength: 9mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $7.5303; ministry $7.5303
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02551039
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103979
Shortage status: not checked (no credentials)